Anirban Maitra: Revolution Medicines has launched its phase 3 study of RMC-6236
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X:
“Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated Pancreatic Cancer.
1:1 randomization against physician’s choice of chemotherapy.
A registration trial for KRAS inhibitor in pancreatic cancer!”
Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023